Allogene Therapeutics (ALLO) Short Interest Ratio & Short Volume

Short interest is the volume of Allogene Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 33,870,000 shares of ALLO short. 32.03% of Allogene Therapeutics' shares are currently sold short. Learn More on Allogene Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALLO shares currently have a short interest ratio of 16.0. Learn More on Allogene Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Allogene Therapeutics: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 32.03% of Allogene Therapeutics' floating shares are currently sold short.

Allogene Therapeutics saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 33,870,000 shares, an increase of 8.0% from the previous total of 31,360,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Allogene Therapeutics currently has issued a total of 170,720,000 shares. Some of Allogene Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Allogene Therapeutics currently has a public float of 105,750,000 shares.

32.03% of Allogene Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Allogene Therapeutics: Alector, Inc. (10.20%), ProKidney Corp. (22.89%), Voyager Therapeutics, Inc. (7.74%), Valneva SE (0.08%), C4 Therapeutics, Inc. (14.74%), Editas Medicine, Inc. (24.93%), Taysha Gene Therapies, Inc. (9.04%), Adaptive Biotechnologies Co. (8.17%), Humacyte, Inc. (4.99%), iTeos Therapeutics, Inc. (7.23%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks.

Short selling ALLO is an investing strategy that aims to generate trading profit from Allogene Therapeutics as its price is falling. ALLO shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Allogene Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALLO, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALLO, twice per month. The most recent reporting period available is April, 30 2024.